Similar results on albuminuria have been attained in a pooled analysis of randomized controlled trials evaluating the effect of dapagliflozin in patients with type 2 diabetes and stages 3b–4 CKD characterized by lower levels of albuminuria (urine albumin–creatinine ratio 40 mg/g) [31]. This evidence concerns the gene ALB and chronic kidney disease.